Latest Operational Efficiency News

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

X2M Connect Limited kicks off FY26 with a 25% revenue surge and a significant reduction in net debt, backed by major new contracts across Asia and the Middle East.

DUG Technology reports a robust start to FY26 with 19% revenue growth and a landmark SaaS and HPCaaS contract, marking key international milestones.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.

Big River Industries reports a 4.9% sales decline year-to-date but highlights stabilizing revenue and resilient margins, with a cautious outlook on residential recovery and steady commercial demand.

BetMakers Technology Group kicks off FY26 with a strong financial turnaround and strategic advances, including a promising acquisition and digital wagering expansion in Nevada.

Focus Minerals reported a record gold pour in August 2025 and steady production at its Coolgardie Gold Project, supported by operational efficiencies and exploration progress.

BetMakers Technology Group has reported a remarkable 361% growth in adjusted EBITDA for Q1 FY26, driven by strong revenue gains and operational efficiencies, while advancing its strategic expansion into the Las Vegas racing market.

XPON Technologies reports a robust Q1 FY26 with 17.5% revenue growth, positive cash flow, and strategic leadership changes, setting a strong foundation for the year ahead.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

Lark Distilling Co. reported a 10% increase in net sales for Q1 FY26, driven by strong domestic and Asian export growth, while preparing for a major brand restage and leadership change.